Should I buy Halozyme (HALO) stock or is it too late?

Halozyme · Health Care · price $110

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 71% of its targets hit on this sector (248 calls tested). It aims for $130 (+19 %), call made on October 9, 2026, maturing on October 9, 2027 (5 d ago).

The 4 reliable analysts $103-6.5 %

The 3 other firms $93-15 %

How to read it: the 4 reliable firms are not filtered by optimism — 2 aim above the price, 2 below, hence their $103 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Halozyme

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Piper Sandler	100 %	+57.4 %	5	$53 -52%
JP Morgan	70 %	+53.4 %	10	$78 -29%
HC Wainwright & Co.	100 %	+33.8 %	39	$130 +19%
Benchmark	78 %	+32.7 %	9	$90 -18%
JMP Securities	64 %	+18.5 %	14	$91 -17%
Morgan Stanley	60 %	+13.0 %	10	$93 -15%
Wells Fargo	67 %	+9.6 %	6	$95 -13%
BMO Capital	80 %	+75.9 %	5	—

In short — Should you invest in Halozyme? Is it too late, still worth it? Analysts are fairly positive (71% buy, median target $94, i.e. -14%), and the most reliable on HALO targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

71% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
The most reliable firm on HALO, HC Wainwright & Co. (100% hit rate, 39 scored calls), targets $130 (call made on October 8, 2026, maturing on October 8, 2027) (+19%) in its most recent call, and $90 (call made on October 15, 2025, maturing on October 15, 2026) (-18%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 7 ratings, 2 are neutral.
Limited upside: the median target is only -14% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on HALO

Median target $94 (-14%) · 7 ratings · Buy consensus

Strong Buy00%

Buy571%

Hold229%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Halozyme now?

We won't decide for you. The facts: 71% of analysts rate it a buy, median target $94 (-14%), and HC Wainwright & Co. (most reliable on HALO, 100%) targets $130. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Halozyme?

The stated upside is small: the median target ($94) sits just -14% from the price ($110) (most reliable on HALO: HC Wainwright & Co., 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Halozyme still worth investing in?

It depends on the gap between the price ($110) and its estimated value: analysts target $94 on median (-14%), with 71% buys (most reliable on HALO: HC Wainwright & Co., 100%). Cross-check with their real reliability on HALO and the cautions above. Information, not advice.

What's the main risk in buying HALO?

The consensus is not unanimous: of 7 ratings, 2 are neutral.

→ Go deeper: the full Halozyme profile (consensus, analyst reliability, price target, performance).